Intracranial injection of CD4+ CAR-T in an NSG model of GBM showed durable anti-tumor efficacy and prolonged survival, while mice receiving CD8+ CAR-T cells recurred following an initial response (233). This evidence concerns the gene CD4 and neoplasm.